Document text
ACIP COVID -19 Vaccines Work Group
Dr. Matthew F. Daley, Work Group Chair
June 27, 2024National Center for Immunization and Respiratory Diseases
•ACIP met September 12, 2023 and recommended 2023 -2024 COVID -19 vaccines as authorized
under EUA or approved by BLA in persons aged ≥6 months
-Moderna COVID -19 vaccine in persons ≥6 months
-Pfizer -BioNTech COVID -19 vaccine in persons ≥6 months
-Novavax COVID -19 vaccine in persons ≥ 12 years*
•Everyone aged 5 years and older should get 1 dose of a 2023 -2024 COVID -19 vaccine to protect
against serious illness from COVID -19
•Children aged 6 months –4 years need multiple doses of COVID -19 vaccines to be up to date,
including at least 1 dose of 2023 -2024 COVID -19 vaccine
•People who are moderately or severely immune compromised may receive additional doses of
COVID -19 vaccines
•On February 28, 2024 ACIP recommended that adults ages 65 years and older receive one additional
2023 -2024 COVID -19 vaccine dose2023 -2024 COVID -19 vaccine recommendations
Abbreviations – EUA: Emergency Use Authorization, BLA: Biologics License Application
*People aged 12 years and older who have not previously received any COVID -19 vaccine doses and choose to get Novavax should get 2 doses of updated Novavax vaccine to be up to date.
•Reviewed evidence to inform recommendations for an additional dose of the 2023 -2024
COVID -19 vaccine for adults ages 65 years and older, including:
-COVID -19 hospitalizations
-COVID -19 vaccine coverage
-COVID -19 vaccine effectiveness
-Economic analysis of additional COVID -19 vaccine doses
-Evidence to Recommendations
•ACIP voted to recommend an additional dose of 2023 -2024 COVID -19 vaccine in persons ≥65
years
•Discussed next steps for the COVID -19 vaccine program, including shifting to a vote at the June
ACIP meeting for future vaccine updatesFebruary 2024 ACIP Meeting Review
•Framing of the policy question for the 2024 -2025 vaccine
-Started with considerations for universal v. risk -based recommendations
•Reviewed international COVID -19 vaccination policies from countries with
risk-based and age -based recommendations
•Discussed complexity of a risk -based recommendation, including
–Defining risk groups for severe outcomes
–Whether to take into account high risk of exposure
–Recommendations for persons not meeting risk criteria, including
those not previously vaccinated
•Discussed i mplementation challenges of non -universal policy options
-Work Group consensus was to proceed with deliberations for a universal
recommendation for everyone ages ≥ 6 months for 2024 -2025 vaccineACIP COVID -19 Work Group Meeting Review –
Initial planning
•Framing of the policy question for the 2024 -2025 vaccine
•Updated data on COVID -19 epidemiology, including risk factors for hospitalization due to
COVID -19 and epidemiology of Multisystem Inflammatory Syndrome in Children (MIS -C) and
Post -COVID Conditions
•Vaccine effectiveness of the 2023 -2024 COVID -19 vaccine
•Review of COVID -19 vaccine safety including longer -term outcomes of myocarditis
•Economic analysis of COVID -19 vaccination
•COVID -19 vaccine program implementation considerations
•Evidence to Recommendations Framework ACIP COVID -19 Work Group Meeting Review
March – June 2024
•June 5, 2024: FDA’s Vaccines and Related Biological Products Advisory
Committee (VRBPAC) met to discuss strain selection for 2024 -2025 COVID -
19 vaccines
-Based on the totality of the evidence presented, FDA advised
manufacturers to develop monovalent JN.1 lineage COVID -19 vaccines,
with a preference for the KP .2 strain, if feasible
-Anticipated 2024 -2025 vaccine doses will be broadly available in the fallCOVID-19 vaccine 2024-2025 Formula: VRBPAC Meeting
https://www.fda.gov/vaccines -blood -biologics/updated -covid -19-vaccines -use-united -states -beginning -fall-2024
COVID -19-associated hospitalizations
COVID-19 vaccine effectiveness update
Vaccine safety update for 2023-2024 COVID-19 vaccine
Economic analysis of COVID-19 vaccination
Evidence to recommendations
COVID-19 vaccine implementation Dr. Fiona Havers
Dr. Ruth Link -Gelles
Dr. Jonathan Duffy
Dr. Lisa Prosser
Dr. Lakshmi Panagiotakopoulos
Dr. Shannon Stokely
Vote: 2024 -2025 COVID -19 vaccines in persons ages 6 months and olderAgenda: June 27, 2024
Work Group members
ACIP members
•Matthew Daley (chair)
•Oliver Brooks
•Robert Schechter
•Keipp Talbot
Ex-officio/government members
•BARDA: Christine Oshansky
•CDC: Alan Lam
•FDA: Rachel Zhang, Adam Spanier
•IHS: Uzo Chukwuma
•NIH: Chris Roberts
CDC co -Leads
•Megan Wallace
•Lakshmi PanagiotakopoulosLiaisons
•AAFP: Jonathan Temte
•AAP: Sean O’Leary
•ACOG: Naima Joseph (primary),
Laura Riley (alternate)
•ACP: Jason Goldman
•AGS: Ken Schmader
•AIM: Heather Roth
•AMA: Sandra Fryhofer
•ANA: Ruth Francis
•APhA : Richard Dang
•ASTHO: Marcus Plescia
•CSTE: Paul Cieslak, Christine Hahn
•IDSA: Jeff Duchin Liaisons, cont’d
•NACCHO: Matt Zahn (primary),
Jeff Duchin (alternate)
•NACI: Eva Wong (primary),
Matthew Tunis (alternate)
•NFID: Robert Hopkins (primary),
Bill Schaffner (alternate)
•SHEA: Preeti Mehrotra (primary),
Marci Drees (alternate)
Consultants
•Beth Bell
•Ed Belongia
•Hank Bernstein
•Kathy Edwards
•Lisa Jackson
•Kathy Kinlaw•Grace Lee
•Dayna Matthew
•Jennifer Nelson
•Stanley Perlman
•Peter Szilagyi
CDC participants
•Sarah Meyer
•Elisha Hall
•Danielle Moulia
•Monica Godfrey
•Hannah Rosenblum
•Katherine Fleming -Dutra
•Ruth Link -Gelles
•Lauren Roper
•Mary Chamberland
•Susan Goldstein
•Stephen Hadler
•JoEllen Wolicki
•Melinda Wharton
•Jessica MacNeil
•Latifa Boyce
•Amadea Britton
•Karen Broder•Carolyn Bridges
•Allison Ciesla
•Nicole Dowling
•Daniel Drapeau
•Kristen Folsom
•Ashley Fowlkes
•Jarrett Gartin
•Julianne Gee
•Samuel Graitcer
•Elizabeth Greene
•Lisa Grohskopf
•Aron Hall
•Demorah Hayes
•Rita Helfand
•Michele Hlavsa
•Terri Hyde
•Jefferson Jones
•Andrew Kroger
•Josephine Mak
•Lauri Markowitz
•Michael McNeil
•Michael Melgar
•Noelle -Angelique Molinari
•Morgan Najdowski
•Kristen Nordlund
•Ismael Ortega -Sanchez
•Manisha Patel
•Pragna Patel
•Amanda Payne
•Georgina Peacock
•Jamison Pike
•Derrell Powers
•Sierra Scarbrough
•Jordan Singleton•Laura Steinhardt
•John Su
•Natalie Thornburg
•Evelyn Twentyman
•David Wentworth
•Dennis Wang
•Raigan Wheeler
•Ryan Wiegand
•Trang Wisard
•Patricia Yu
•Yon Yu
For more information, contact CDC
1-800-CDC-INFO (232- 4636)
TTY: 1- 888- 232-6348 cdc.gov
The findings and conclusions in this report are those of the authors and do not necessarily represent the official
position of the U.S. Centers for Disease Control and Prevention.